RxDoctor Payments Data

Danajo Woods

Family · Toledo, OHNPI 1659897387

Payments from drug & device makers

$5,707in general payments, 2019–2025

Across 284 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$573
  • Johnson & Johnson$431
  • UCB, Inc.$385
  • Amgen$360
  • EMD Serono, Inc.$319
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$1753%
  • Food & beverage$5,52497%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,707 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$43,498
Medicare patients
247
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate15$103,753
Nurtec OdtRimegepant Sulfate42$47,887
Aimovig AutoinjectorErenumab-Aooe41$43,931
RexultiBrexpiprazole24$27,760
Ajovy AutoinjectorFremanezumab-Vfrm16$11,533
Emgality PenGalcanezumab-Gnlm15$11,407
Rivastigmine40$7,298
Carbidopa-LevodopaCarbidopa/Levodopa141$4,486
Memantine Hcl126$3,550
Entacapone24$3,349
Gabapentin143$2,308
Levetiracetam83$2,138
Carbidopa-Levodopa ErCarbidopa/Levodopa52$2,097
RivastigmineRivastigmine Tartrate31$2,084
Pregabalin45$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$220$103,75315 claims
PfizerNurtec Odt$213$47,88742 claims
Otsuka America Pharmaceutical, Inc.Rexulti$175$27,76024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →